MHRA clears inavolisib, offering new option for returning breast cancer
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
The audit was completed with zero critical and zero major observations
The 7,000th store was inaugurated in Ayodhya, Uttar Pradesh
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Renalyx will continue operating as an independent unit within the group
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Subscribe To Our Newsletter & Stay Updated